euro adhoc - Meldung

13.05.2008 - euroadhoc / Börse / stock market / quarterly or semiannual financial statement / 3-month report
euro adhoc: Intercell AG / quarterly or semiannual financial statement / Intercell AG announces Q1 2008 results and update on development programs: Vaccine against Japanese Encephalitis moving towards global market approvals: US FDA inspection currently ongoing, Australia grants priority review - All development programs on track (E)=

--------------------------------------------------------------------------------
  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
--------------------------------------------------------------------------------
13.05.2008
Intercell's investigational Japanese Encephalitis vaccine expected to obtain
market approval in global traveler markets in 2008 - commercial production
started
» Intercell´s manufacturing facility in Livingston receives Manufacturer's  
  License from MHRA for future commercial manufacturing of the vaccine against 
  Japanese Encephalitis
» Day-80 review from EMEA (European Medicines Agency) received
» FDA waives VRPAC (Vaccines and Related Biological Products Advisory  
  Committee) - Pre-approval inspection of the facilities started on time and  
  is currently ongoing
» Licensure application submitted to Australian Therapeutic Goods  
  Administration (TGA) - TGA grants priority review for Intercell's vaccine  
  candidate
» Licensure application for approval in Switzerland to Swissmedic submitted  
  via Novartis
» EU, US and Australian market approvals expected in 2008
» Vaccine shows excellent safety and immunogenicity in Phase II trials in  
  children at "half dose"
Significant progress in vaccines against hospital-acquired infections 
» S. aureus: Phase II results for vaccine designed by Intercell expected for  
  end 2008 / early 2009 (conducted by Merck & Co., Inc.)
» Pseudomonas : Start of clinical Phase II/III trials expected for 2008 
» Pneumococcus: Outstanding pre-clinical results on novel protein-based  
  universal vaccine published in the Journal of Experimental Medicine;  
  initiation of Phase I trials is planned for later in 2008
» Acceleration of pre-clinical candidates for further nosocomial vaccine and  
  antibody product targets including Klebsiella and Enterococcus
Unique clinical data for therapeutic Hepatitis C vaccine
» Therapeutic Hepatitis C vaccine candidate meets primary endpoints in  
  Phase II trials - data from 46 vaccinated chronic patients reveal  
  statistically significant viral load reduction and favorable safety profile
» Intercell and Novartis initiated co-development; further clinical trials  
  will include IC31®
» Intercell was awarded "The Vaccine Industry Excellence Award" in the  
  category of "Best New Therapeutic Vaccine" for its therapeutic Hepatitis C  
  vaccine candidate at the "World Vaccine Congress" in Washington D.C.
Adjuvant IC31® - Phase I Influenza trials with IC31® successfully completed -
Collaboration on Malaria - Tuberculosis cooperation expanded 
» Influenza: Intercell's adjuvant IC31® demonstrates a very good safety and  
  tolerability profile in first Phase I Influenza vaccine clinical trial
» Malaria: ICLL and PATH Malaria Vaccine Initiative (MVI) initiated a new  
  collaboration to evaluate adjuvant IC31® in combination with malaria  
  antigens from the US National Institutes of Health (NIH) 
» Tuberculosis: TB vaccine formulated with adjuvant IC31® and developed in a  
  partnership between Statens Serum Institut (SSI) and Sanofi Pasteur enters a 
  series of further clinical trials 
Strong financial and strategic position - Costs under control, fully on track
for strong increase in revenues and sustained profitability for the full year
2008
» EUR 4.6 m net loss for Q1 2008 compared to EUR 7.1 m in Q1 2007, a reduction 
  of 35.2 percent
» Increase in aggregate revenues - EUR 8.6 m in Q1 2008 compared to EUR 1.5 m  
  in Q1 2007, an increase of 473.3 percent
» EUR 10.4 m R&D expenses in Q1 2008 - up 41.0 percent compared to EUR 7.4 m  
  in Q1 2007 following progress of development programs as planned
» Strong strategic cash position: EUR 272.2 m in liquid funds at March 31,  
  2008. Further EUR 40 m already unconditionally committed for 2008.
» Intercell will finance the cash component of the acquisition of Iomai  
  Corporation, which was announced today, comfortably from existing reserves.  
  Despite higher costs through the acquisition, Intercell also expects to  
  maintain its target of profitability in 2008.
Key Financial Figures 
TEUR                       3 months ended       Year ended
                         March 31, March 31,       Dec 31,
                           2008      2007           2007
Revenues                   8,625     1,502         53,349
Net profit/(loss)          (4,617)   (7,050)         5,009
Net operating cash flow   (12,808)   (9,635)       (41,686)
Cash and available-for-
sale financial assets      272,223    86,262        287,571

Further inquiry note:
Intercell AG 
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com
emitter:      Intercell AG
              Campus Vienna Biocenter  6
              A-1030 Wien 
phone:        +43 1 20620-0
FAX:          +43 1 20620-800
mail:         investors@intercell.com 
WWW:          www.intercell.com
sector:       Biotechnology
ISIN:         AT0000612601
indexes:      ATX Prime, ATX
stockmarkets: official market: Wiener Börse AG 
language:     English